Embecta Corp (EMBC) Fair Value & Analysis
Healthcare · US · Market cap $185M · ISIN US29082K1051
Embecta Corp
EMBC · US
Strengths
Risks
Fair value as of: Aug 13, 2026
From 21 valuation models · updated 15 days ago
Fair value updated Aug 13, 2026, revised from $3.25 to $3.15 (−3.0%) since Jul 15, 2026. Share price +37.2% over the past month.
A solid business, but trading 60% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- A high-quality business (quality 73/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case ($3.82). The favourable scenario is already priced in.
Price vs Fair Value (4 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
53‑month range $2.89 – $48.11 · fair‑value band $2.39 – $3.82 · the $5.05 price screens above the $3.15 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Embecta Corp (EMBC) currently trades at $5.05, while our model-based Fair Value estimate is $3.15, implying the stock looks roughly 37.7% overvalued today. The Quality Score stands at 73/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Embecta Corp generated revenue of $1.0B at a net margin of 10.7%. Revenue declined 14.4% year over year. Net debt stands at $1.2B. The stock trades on a trailing P/E of 2.7. Fundamentals as of Aug 13, 2026
Our scenario range runs from $2.39 (bear case) to $3.82 (bull case); at $5.05, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high and 83% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -47% fair-value upside, at -38%, EMBC screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 21 models by family
Widest divergence: Multiples ($35.38) versus Dividend Discount ($4.39). Highest evidence: Growth DCF (80).
Notify me when EMBC reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Full company description
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Embecta Corp reported revenue of $1.1B in FY2025 versus $1.2B in FY2021, a compound −1.9%/yr. Reported net income was $95.4M in FY2025, compounding −30.7%/yr from FY2021.
EMBC screens 38% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 206 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $367.07 | $150.04 | -59% |
| EssilorLuxottica Société anonyme EL | €157.50 | €94.93 | -40% |
| Medline Inc MDLN | $34.58 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $190.21 | $100.46 | -47% |
| Alcon Inc ALC | $72.23 | $39.78 | -45% |
| ResMed Inc RMD | A$32.39 | A$26.05 | -20% |
| West Pharmaceutical Services, Inc WST | $349.92 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €196.70 | €48.88 | -75% |
| Straumann Holding STMN | CHF 92.18 | CHF 47.31 | -49% |
| Sartorius Aktiengesellschaft SRT3 | €253.50 | €63.30 | -75% |
Compare Embecta Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Embecta Corp (EMBC) overvalued or undervalued?
What is the fair value of EMBC?
What is the quality score of EMBC?
What is the revenue of Embecta Corp (EMBC)?
What is the net profit margin of EMBC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Watch Embecta Corp in the live analysis
One click puts Embecta Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.